Overview

Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab
Capecitabine
Cisplatin
Docetaxel